IBB Is Positioned For Outperformance
December 06, 2019 at 08:33 AM EST
iShares Nasdaq Biotechnology ETF is benefitting from reduced regulatory risk in the middle term. The ETF is still trading below its highs of 2015, so it has a lot of ground to recover going forward.
